Co-occurrence of two cases of progressive multifocal leukoencephalopathy in a natalizumab "infusion group"

Mult Scler. 2013 Aug;19(9):1213-5. doi: 10.1177/1352458512466165. Epub 2012 Nov 1.

Abstract

We observed two cases of progressive multifocal leukoencephalopathy (PML) that occurred in the same "infusion group". The group consisted of four patients with relapsing-remitting multiple sclerosis (RRMS) who had been treated with natalizumab (NAT) in the same medical practice for more than four years at the same times and in the same room, raising concerns about viral transmission between members of the infusion group. DNA amplification and sequence comparison of the non-coding control region (NCCR) of JC virus (JCV) present in cerebrospinal fluid (CSF) samples from PML patients #1 and #2 revealed that the amplified JCV sequences differed from the JCV archetype. The NCRR of the viral DNA was unique to each patient, arguing against the possibility of viral transmission between patients. Statistical considerations predict that similar co-occurrences of PML are likely to happen in the future.

Keywords: JC virus; Natalizumab; PML; multiple sclerosis; progressive multifocal leukoencephalopathy.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal, Humanized / administration & dosage*
  • Antibodies, Monoclonal, Humanized / adverse effects
  • Female
  • Humans
  • JC Virus / genetics
  • Leukoencephalopathy, Progressive Multifocal / complications*
  • Leukoencephalopathy, Progressive Multifocal / transmission
  • Leukoencephalopathy, Progressive Multifocal / virology
  • Male
  • Middle Aged
  • Multiple Sclerosis, Relapsing-Remitting / drug therapy*
  • Multiple Sclerosis, Relapsing-Remitting / virology
  • Natalizumab
  • Reverse Transcriptase Polymerase Chain Reaction

Substances

  • Antibodies, Monoclonal, Humanized
  • Natalizumab